Medically Reviewed & Authored by: George King
R&D Manager & Emergency Preparedness Specialist at Fitiger Life LLC.
George specializes in non-clinical intervention systems and institutional safety protocols.
Before March 2026, this product space was crowded with claims and short on category clarity. FDA's De Novo grant changed that. DEN250012 created a named federal device type, assigned it a regulation number, fixed it in Class II, and gave procurement teams a lawful reference point that had not existed before.
The generic type is narrow by design. FDA defined it as a 'suction anti-choking device as a second-line treatment' intended to resolve choking in victims with complete airway obstruction after unsuccessful use of a basic life support choking protocol. That wording matters more than the headline language around 'authorization'. It locks the category to sequence, indication, and timing.
The same March 4, 2026 safety communication also drew a sharp line around the market. FDA said one anti-choking device had been authorized for marketing and distribution in the United States. Registration and listing still do not denote approval, clearance, or authorization. That sentence changed how serious buyers should read vendor claims.
First-line choking response did not move. Back blows, abdominal thrusts, chest thrusts for infants, and the broader BLS sequence still own the first seconds.
FDA was explicit about the limit. The special controls and labeling requirements keep the device in a backup role. The category exists after unsuccessful use of a BLS choking protocol, not before it. Schools, care settings, and employers do not get to reverse that order because a second-line tool is mounted nearby.
The agency also warned that retrieving, unpacking, and assembling an anti-choking device before attempting standard rescue measures can delay critical treatment. That warning cuts straight through a lot of bad deployment logic. A wall station does not help if it changes the order of care.
Most summaries stopped at 'FDA granted authorization'. The more important story sits inside the special controls. FDA did not leave this category in a vague over-the-counter gray zone. It forced the device type to prove something harder: that the category could be managed through a mix of clinical evidence, postmarket surveillance, bench testing, human factors, training, labeling, and biocompatibility controls.
Read the special controls line by line and the safety logic becomes obvious. FDA wanted data on how often the device is used after unsuccessful BLS, how much delay the device introduces before BLS starts, how often the device resolves choking, and what injuries or malfunctions show up in real use. The category is regulated around sequence integrity, not just suction generation.
Non-clinical testing also had to verify three mechanical things: performance in dislodging a complete obstruction in representative simulated airway models, pressures generated, and device and material durability. That is a much higher bar than a product demo video.
Pressure matters because suction has to do real mechanical work. It has to create enough negative pressure to move an obstruction toward the mouth without introducing a different failure mode.
In independent bench testing published in Resuscitation Plus in 2026, a certified Fitiger generated mean peak negative pressure of 25.5 +/- 9.6 kPa, compared with 8.2 +/- 3.9 kPa for a visually similar uncertified counterfeit device. That was a mean difference of 17.3 kPa and roughly a 3x suction gap.
That result does not prove that every authorized device will succeed in every clinical scenario, and it does not erase the need for more independent real-world data. It does show something procurement teams need to understand: the physical boundary between an FDA-authorized Class II device and a lookalike copy can be large enough to matter. Category compliance and performance floor are linked now.
One of the quietest but most important engineering points in the De Novo summary is the airflow path. FDA's device description says the handle is pressed down to compress the unit, pushing air out through the vent system on the bottom of the device and not into the patient. The handle is then pulled up to generate negative pressure.
That design logic is not cosmetic. It addresses a core hazard: pushing an obstruction deeper into the airway. FDA's description also states that the patented ball-valve system is designed to prevent air from exiting through the mask and to prevent air from pushing stuck food or foreign objects downward, creating one-way suction to remove the lodged object.
That is the mechanical redundancy safety teams should care about. An anti-choking device in this class is not just a plunger with a mask. It is supposed to be an outbound-only path on compression and an inbound negative-pressure path on pull. A copy that cannot hold that boundary is not merely a cheaper version. It is a different risk profile.
Human factors does not mean 'easy to use' in a vague consumer sense. It means the interface, instructions, sequence, and training have to hold up under stress well enough for the intended user to perform the right tasks in the right order.
FDA's De Novo summary says human factors validation was performed under the agency's 2016 human factors guidance, using both laypeople and health care professionals, with naive and familiarized users. The benefit-risk section says users were able to assemble and use the device within 169 seconds in simulated use, and FDA treated that timing as relevant to the 240-second window when permanent hypoxic brain injury begins to develop.
Independent simulated-use work published earlier with parents and kindergarten teachers reported a median test time of 36.6 seconds for LifeVac in a controlled scenario. That number should not be oversold as a field guarantee. It still matters. It shows that usability can be fast when the interface is simple, the mask is clear, and the user is not fighting the device itself.
Human factors is also where FDA's caution lives. The De Novo summary describes persistent use errors and close calls, including failure to call 911, bypassing the standard choking protocol, incorrect mask selection, and not tilting the head back. The lesson is straightforward: second-line devices do not remove workflow risk. They relocate it into training, labeling, and sequence discipline.
This classification directly dictates school, care-setting, and employer procurement standards in a way the pre-2026 market never did. Buyers can now write to a named federal category, a regulation number, a product code, and a defined intended-use statement. They can separate authorized products from listed-but-unauthorized products without hiding behind vague 'anti-choking device' language.
That changes risk review. A serious procurement file should now answer four plain questions: Is the product authorized inside the current FDA framework? Is the deployment built around first-line BLS first and second-line use second? Does the placement reduce retrieval latency in the real room that matters? Can the institution prove who was trained, where the unit sits, who checks it, and what happens after use?
That is where the 2026 decision has the most practical force. It did not make the category simple. It made sloppy decisions easier to spot.
Do not ask whether FDA 'approved anti-choking devices' in the abstract. That question is too loose to manage risk.
Ask narrower questions. Which product was granted DEN250012? Which generic device type did 21 CFR 874.5400 create? What did FDA keep inside the second-line definition? What pressure, valve-path, human-factors, and postmarket requirements now sit underneath the category? What happens to your procurement file if the device on the invoice is merely listed, not authorized?
Read the order before you write the claim. Time the route before you mount the unit. Verify the device status before you let the purchase clear. Then review whether your deployment keeps first-line care first and second-line care fast.
It granted a De Novo classification for LifeVac and created 21 CFR 874.5400 for a Class II 'suction anti-choking device as a second-line treatment'.
No. The category is defined for complete airway obstruction after unsuccessful use of a BLS choking protocol.
Because the safety logic depends on venting air away from the patient during compression and avoiding downward displacement of the obstruction.
No. FDA states that registration and listing do not denote approval, clearance, or authorization.
Because the 2026 category is not just a legal label. Bench verification of generated pressures is one of the FDA special controls, and independent testing has shown large performance gaps between a certified device and a visually similar counterfeit.
|
Evidence point |
Value / requirement |
Why it matters |
|
De Novo identifier |
DEN250012 |
Anchors the 2026 federal classification event and all downstream procurement language. |
|
Regulation / code |
21 CFR 874.5400 / QXN |
Lets institutions write to a defined FDA category rather than vendor copy. |
|
Device class |
Class II |
Signals that the category is governed by special controls, not a low-oversight consumer bucket. |
|
Independent bench pressure comparison |
20.5 +/- 7.6 kPa vs. 8.2 +/- 3.9 kPa |
Shows a roughly 2.5x suction gap between a certified device and a visually similar counterfeit in bench testing. |
|
FDA human factors timing |
Assembly and use within 169 seconds |
Puts usability inside the agency's benefit-risk reasoning. |
|
Independent simulated-use timing |
Median 36.6 seconds |
Supports the claim that fast operation is possible in controlled hands, while still not guaranteeing field performance. |
FDA De Novo Summary, DEN250012
FDA De Novo database entry for DEN250012
FDA safety communication, March 4, 2026
Resuscitation Plus 2026 bench comparison
Resuscitation 2022 pilot simulated-use letter
AHA newsroom summary of the 2025 choking sequence update
Medical Disclaimer
This article is for educational and operational planning purposes only. It does not provide medical or legal advice. In any real emergency, follow current American Heart Association or Red Cross choking-response guidance, activate trained first-line response immediately, and call 911.
